Mexico beckons with regulatory reforms but 'innate opaqueness' a concern
This article was originally published in SRA
Regulatory reforms and a significant clearing up of a product approvals backlog in Mexico are expected to facilitate a spurt in activity in the country by international companies including leading Indian firms, though some experts claim that "invisible barriers" for products from foreign destinations still pose challenges1,2.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.